Drug factory · FDA FEI 3025560903
Shilpa Pharma Lifesciences Limited
Plot. No. 1A &1A P, 1B, 2, 2A, 2B, 3A to 3E, 4A, 5A, 4B & 5B Deosugur Industrial Area, Deosugur, Raichur, India
Problems found, fixed voluntarily at FDA's last inspection, Mar 7, 2025.
Voluntary Action Indicated: inspectors found problems, but not serious enough for FDA to take action. The company is expected to fix them.
1 drug inspection on record since 2025: 0 with no problems, 1 with problems fixed voluntarily, 0 with FDA action.
What it does, for whom
| Drug | Role | For | NDC |
|---|---|---|---|
| Gemcitabine | Makes the active ingredient and tests it | Janssen Biotech, Inc. | 57894-225 |
FDA inspection history
| Ended | Result | Program | Problems noted |
|---|---|---|---|
| Mar 7, 2025 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
Registered with FDA for: analysis; api manufacture.